The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine and oxaliplatin versus capecitabine alone in locally advanced rectal cancer: Disease-free survival results at interim analysis.
Hans-Joachim Schmoll
Consultant or Advisory Role - Bayer; Roche
Honoraria - Bayer; Roche
Research Funding - Merck
Karin Haustermans
No relevant relationships to disclose
Timothy Jay Price
Consultant or Advisory Role - Roche (U)
Bernard Nordlinger
No relevant relationships to disclose
Ralf Hofheinz
Consultant or Advisory Role - Roche
Honoraria - Roche
Research Funding - Roche
Jean-Francois Daisne
No relevant relationships to disclose
Jozef Janssens
No relevant relationships to disclose
Baruch Brenner
No relevant relationships to disclose
Peter Schmidt
No relevant relationships to disclose
Hans Reinel
No relevant relationships to disclose
Stephan Hollerbach
No relevant relationships to disclose
Karel Caca
No relevant relationships to disclose
Florian W.B. Fauth
No relevant relationships to disclose
Carla Hannig
No relevant relationships to disclose
John Raymond Zalcberg
Honoraria - Roche; Sanofi
Research Funding - Roche; Sanofi
Niall C. Tebbutt
No relevant relationships to disclose
Murielle E. Mauer
No relevant relationships to disclose
Carlo G. M. Messina
No relevant relationships to disclose
Manfred P. Lutz
Consultant or Advisory Role - Sanofi
Eric Van Cutsem
No relevant relationships to disclose